Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Short Interest Up 451.9% in April

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) saw a large growth in short interest in April. As of April 30th, there was short interest totaling 70,535 shares, a growth of 451.9% from the April 15th total of 12,780 shares. Based on an average daily trading volume, of 113,858 shares, the short-interest ratio is presently 0.6 days. Currently, 0.1% of the company’s stock are sold short.

Hedge Funds Weigh In On Xtant Medical

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Nantahala Capital Management LLC raised its position in Xtant Medical by 500.3% during the 2nd quarter. Nantahala Capital Management LLC now owns 68,394,000 shares of the medical device company’s stock worth $50,543,000 after buying an additional 57,000,000 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Xtant Medical by 4.6% in the third quarter. Vanguard Group Inc. now owns 2,355,671 shares of the medical device company’s stock worth $1,529,000 after acquiring an additional 104,159 shares during the period. Renaissance Technologies LLC raised its holdings in shares of Xtant Medical by 28.8% during the fourth quarter. Renaissance Technologies LLC now owns 919,860 shares of the medical device company’s stock worth $721,000 after purchasing an additional 205,945 shares during the last quarter. Hillsdale Investment Management Inc. purchased a new position in shares of Xtant Medical during the fourth quarter worth $284,000. Finally, Nano Cap New Millennium Growth Fund L P acquired a new position in Xtant Medical during the fourth quarter valued at $220,000. Institutional investors and hedge funds own 69.33% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on XTNT shares. Craig Hallum restated a “buy” rating on shares of Xtant Medical in a research note on Wednesday, March 18th. BTIG Research reiterated a “buy” rating and issued a $1.00 target price on shares of Xtant Medical in a research note on Wednesday. Two analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $1.00.

Xtant Medical Stock Performance

Shares of NYSEAMERICAN XTNT traded down $0.01 during mid-day trading on Thursday, hitting $0.47. The stock had a trading volume of 144,246 shares, compared to its average volume of 136,695. The firm has a market cap of $65.83 million, a PE ratio of 47.05 and a beta of -0.11. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.63 and a current ratio of 2.65. The company has a 50 day moving average of $0.54 and a two-hundred day moving average of $0.63. Xtant Medical has a twelve month low of $0.44 and a twelve month high of $0.95.

Xtant Medical (NYSEAMERICAN:XTNT) last issued its quarterly earnings results on Wednesday, May 13th. The medical device company reported ($0.02) EPS for the quarter, hitting analysts’ consensus estimates of ($0.02). The company had revenue of $20.88 million during the quarter, compared to analysts’ expectations of $20.16 million. Xtant Medical had a return on equity of 3.66% and a net margin of 1.50%.

Xtant Medical Company Profile

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.